Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 10/20 | 0.37 |
| ▸ | PGR | P06401 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981552 | 1.00 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4982043 | 1.00 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4822515 | 1.00 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4818856 | 0.92 | NR3C1 (0.43) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4818843 | 0.92 | NR3C1 (0.43) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4818715 | 0.89 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL5393545 | 0.89 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4815685 | 0.89 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4981558 | 0.88 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4822944 | 0.87 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129332-A1 | Processes to prepare eplerenone | PHARMACIA & UPJOHN COMPANY | 2007-06-07 | — | — | US | claimed |
| US-20050267302-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | G.D. SEARLE & CO. (US) | 2005-12-01 | — | — | US | claimed |
| US-20050159594-A1 | Eplerenone crystal form exhibiting enhanced dissolution rate | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | claimed |
| EP-1505072-A2 | Eplerenone crystalline form exhiniting enhanced dissolution rate | Pharmacia Corporation (US) | 2005-02-09 | — | — | EP | claimed |
| EP-1487859-A2 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-22 | — | — | EP | claimed |
| US-20030232981-A1 | Contacting a Delta 3,5-3-enol ether of formula (alkyl enol ether) with a hydride abstractor and an alcohol | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | claimed |
| WO-2003082895-A2 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN COMPANY (US) | 2003-10-09 | — | — | WO | claimed |
| US-20020038021-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | PHARMACIA CORPORATION | 2002-03-28 | — | — | US | claimed |
| US-20090149431-A1 | Eplerenone Drug Substance Having High Phase Purity | BARTON KATHLEEN P | 2009-06-11 | — | — | US | disclosed |
| US-7417140-B2 | 17 beta -Hydroxy-7 alpha -(2'-hydroperoxy-2'-methoxyacetyl)pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma -lactone chemical intermediate useful to prepare eplerenone a hypotensive agent, useful for treating congestive heart failure | PFIZER INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7414127-B2 | used to prepare eplerenone; intermediates | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1487859-B1 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN CO LLC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7411062-B2 | 17-Beta -hydroxy-7-alpha-(2'-oxoacetyl or alkanoylcarbonyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma -lactone; intermediate for preparing eplerenone | PFIZER INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1289507-B1 | USE OF AN ALDOSTERONE ANTAGONIST FOR THE TREATMENT OR PROPHYLAXIS OF ALDOSTERONE-MEDIATED PATHOGENIC EFFECTS | PHARMACIA CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20030083493-A1 | Eplerenone drug substance having high phase purity | BARTON KATHLEEN P (US) | 2003-05-01 | — | — | US | disclosed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | disclosed |
| US-20020123485-A1 | Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2002-09-05 | — | — | US | disclosed |
| US-20020111337-A1 | Use of an aldosterone receptor antagonist to improve cognitive function | PHARMACIA CORPORATION | 2002-08-15 | — | — | US | disclosed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020038021-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | PHARMACIA CORPORATION | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111337-A1 | Use of an aldosterone receptor antagonist to improve cognitive function | NR3C2, MC2R, AGTR1 | NR3C1 8/4885TDP1 2608/4885MEN1 3115/4885 |
| US-20050159594-A1 | Eplerenone crystal form exhibiting enhanced dissolution rate | NR3C2, MC2R, HSD11B2 | NR3C1 19/4885TDP1 4507/4885MEN1 1755/4885 |
| US-20050267302-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | NR3C2, MC2R, HSD11B2 | NR3C1 20/4885TDP1 4447/4885MEN1 1812/4885 |
| US-20020038021-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | NR3C2, MC2R, HSD11B2 | NR3C1 20/4885TDP1 4447/4885MEN1 1812/4885 |
| US-20020123485-A1 | Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB2, ADRB1, NR3C2 | NR3C1 31/4885TDP1 4865/4885MEN1 2795/4885 |
| US-20030083493-A1 | Eplerenone drug substance having high phase purity | NR3C2, MC2R, PTGER1 | NR3C1 8/4885TDP1 4324/4885MEN1 1415/4885 |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | PTGER1, KCNN4, HCN1 | NR3C1 68/4885TDP1 4583/4885MEN1 1738/4885 |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | KCNN4, NR3C2, EDNRA | NR3C1 88/4885TDP1 4882/4885MEN1 1977/4885 |
| US-20090149431-A1 | Eplerenone Drug Substance Having High Phase Purity | NR3C2, MC2R, PTGER1 | NR3C1 8/4885TDP1 4324/4885MEN1 1415/4885 |
| US-20030232981-A1 | Contacting a Delta 3,5-3-enol ether of formula (alkyl enol ether) with a hydride abstractor and an alcohol | NR3C2, HSD3B2, HSD11B2 | NR3C1 19/4885TDP1 4733/4885MEN1 664/4885 |
| US-20070129332-A1 | Processes to prepare eplerenone | HSD17B7, CYP11B2, CYP4A11 | NR3C1 71/4885TDP1 4727/4885MEN1 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.